Denali Therapeutics Inc. $DNLI Stock Holdings Lessened by Swiss National Bank

Swiss National Bank trimmed its stake in Denali Therapeutics Inc. (NASDAQ:DNLI) by 1.0% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 250,900 shares of the company’s stock after selling 2,600 shares during the quarter. Swiss National Bank owned 0.17% of Denali Therapeutics worth $3,411,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also made changes to their positions in the stock. Price T Rowe Associates Inc. MD lifted its position in shares of Denali Therapeutics by 6.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,058,615 shares of the company’s stock worth $62,335,000 after purchasing an additional 188,820 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Denali Therapeutics by 19.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,855,036 shares of the company’s stock worth $37,805,000 after purchasing an additional 295,594 shares in the last quarter. Northern Trust Corp lifted its position in shares of Denali Therapeutics by 10.7% in the fourth quarter. Northern Trust Corp now owns 1,201,518 shares of the company’s stock worth $24,487,000 after purchasing an additional 115,876 shares in the last quarter. Stempoint Capital LP lifted its position in shares of Denali Therapeutics by 107.2% in the fourth quarter. Stempoint Capital LP now owns 584,328 shares of the company’s stock worth $11,909,000 after purchasing an additional 302,278 shares in the last quarter. Finally, Polar Asset Management Partners Inc. lifted its position in shares of Denali Therapeutics by 1,240.9% in the fourth quarter. Polar Asset Management Partners Inc. now owns 551,092 shares of the company’s stock worth $11,231,000 after purchasing an additional 509,992 shares in the last quarter. 92.92% of the stock is owned by hedge funds and other institutional investors.

Denali Therapeutics Trading Down 2.0%

NASDAQ:DNLI opened at $14.51 on Thursday. The stock’s 50 day moving average price is $14.28 and its 200 day moving average price is $15.18. Denali Therapeutics Inc. has a 52 week low of $10.57 and a 52 week high of $33.33. The company has a market capitalization of $2.12 billion, a P/E ratio of -5.18 and a beta of 1.36. The company has a debt-to-equity ratio of 0.01, a quick ratio of 10.27 and a current ratio of 10.27.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings data on Monday, August 11th. The company reported ($0.72) EPS for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.02. During the same period last year, the company posted ($0.59) earnings per share. On average, research analysts forecast that Denali Therapeutics Inc. will post -2.71 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. Morgan Stanley reduced their price target on shares of Denali Therapeutics from $33.00 to $30.00 and set an “overweight” rating for the company in a research report on Monday. Robert W. Baird reduced their price target on shares of Denali Therapeutics from $30.00 to $29.00 and set an “outperform” rating for the company in a research report on Thursday, May 8th. TD Cowen raised shares of Denali Therapeutics to a “strong-buy” rating in a research report on Monday, July 28th. William Blair upgraded Denali Therapeutics to a “strong-buy” rating in a report on Thursday, April 24th. Finally, Wedbush dropped their price objective on Denali Therapeutics from $32.00 to $30.00 and set an “outperform” rating on the stock in a report on Wednesday, May 7th. Three analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $33.62.

Insider Buying and Selling

In related news, CEO Ryan J. Watts sold 495,282 shares of the company’s stock in a transaction on Wednesday, July 9th. The shares were sold at an average price of $15.00, for a total transaction of $7,429,230.00. Following the completion of the sale, the chief executive officer directly owned 253,071 shares of the company’s stock, valued at approximately $3,796,065. This represents a 66.18% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Alexander O. Schuth sold 2,937 shares of the company’s stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $13.58, for a total transaction of $39,884.46. Following the sale, the insider directly owned 242,346 shares of the company’s stock, valued at approximately $3,291,058.68. This represents a 1.20% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 501,962 shares of company stock valued at $7,520,799. Company insiders own 12.50% of the company’s stock.

Denali Therapeutics Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.